Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:36:30.244Z.
Calculation as of: 2026-10-06T15:36:30.244Z.
Quote observation: 2026-10-06T15:32:45.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5811ce025d9976e80ea69b9f8bae613fc78d61205a97c72640e2bc4d521a59ba
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | $51.91M | N/A | N/A | N/A | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $52.26M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.98M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $51.83M | 10.99% | 20.03% | 16.76% | 21.84% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.45M | N/A | N/A | N/A | N/A |
| Apollomics, Inc. (APLM)vs › | $51.39M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $51.03M | N/A | 0.59% | 0.59% | 0.59% |
| INmune Bio, Inc. (INMB)vs › | $51.18M | N/A | 3.11% | 2.71% | 2.71% |
| Microbot Medical Inc. (MBOT)vs › | $50.81M | N/A | 0.89% | 5.54% | 4.70% |
| ImageneBio Inc (IMA)vs › | $53.69M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
